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Background: Diabetes has been associated with an increased risk of peripheral arterial
disease (PAD) and worse outcomes following treatment. The DEFINITIVE LE study was
a global study that assessed the effectiveness of plaque excision using the SilverHawk®
and TurboHawkTM systems (Covidien/ev3, Plymouth, MN) for endovascular treatment
of PAD in femoropopliteal and tibial-peroneal arteries.
Methods: 800 patients with a total of 1023 infrainguinal lesions were enrolled in
DEFINITIVE LE and underwent revascularization with plaque excision. Follow-up
assessments occurred at pre-discharge, 30 days, 3 months (for patients with RCC 5 or 6),
6 months and 1 year post-procedure. Endpoints were assessed by independent angio-
graphic and duplex core laboratories and adverse events were adjudicated by a Clinical
Events Committee. The primary endpoint for claudicants was primary patency (defined
using both PSVR  2.4 and PSVR  3.5and estimated by Kaplan-Meier methods).
Secondary assessments included change in Rutherford Clinical Category, ankle-brachial
index, the Walking Impact Questionnaire, EQ-5D quality of life and adverse events.
Results: Preliminary results are shown pending database closure and monitoring; final
results will be presented at TCT 2012. The study enrolled 600 subjects (745 lesions) with
claudication, 46.7% (280/600) of which had diabetes. Subjects with diabetes differed
significantly from those without diabetes in multiple baseline characteristics, but acute and
1-year outcomes were largely similar. Demographics, lesion characteristics and outcomes
are shown below.
Characteristic/
Outcome
Diabetics
(n280,
345 lesions)
Non-diabetics
(n320,
400 lesions) P-value
Age (yrs) 67.6 9.7 71.1 10.8 0.001
Female 41.4% 46.3% 0.24
Caucasian 63.2% 79.4% 0.001
History and risk
factors
Hypertension 95.0% 88.8% 0.007
CHF 18.6% 8.4% 0.001
Renal insufficiency 22.9% 11.3% 0.001
Myocardial
infarction
22.9% 14.7% 0.011
Current or former
smoker
47.1% 59.4% 0.003
Mean lesion length
(cm)
7.6 5.3 7.5 5.3 0.84
Baseline diameter
stenosis
71.9% 17.1% 73.5% 19.0% 0.25
Post-plaque excision
stenosis
23.8% 12.3% 23.9% 13.7% 0.89
Device success 78.4% 74.0% 0.17
1-year primary
patency (PSVR 2.4)
77.2% 74.0% 0.46
1-year primary
patency (PSVR 3.5)
80.9% 79.9% 0.64
Conclusions: Plaque excision is an effective treatment modality for patients with
diabetes. It may be particularly appealing in diabetic patients because it removes the
plaque, opens the lumen and preserves future treatment options in this progressive disease.
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Background: Diabetes mellitus is associated with accelerated progression of coronary
artery disease and impaired outcome after percutaneous coronary interventions. The aim
of this study was to evaluate angiographic and clinical outcomes after the implantation of
everolimus-eluting Xience V/Promus (EES) and sirolimus-eluting Cypher Select	 (SES)
stents in patients with diabetes.
Methods: The study was a Danish multicenter, open-label, randomized trial. We
randomized 213 patients with diabetes and coronary artery disease to EES (n108) or
SES (n105) implantation. Angiographic follow-up was performed after 10 months. All
patients were followed clinically for 18 months. The primary end point was angiographic
in-stent late luminal loss. Secondary end points included angiographic restenosis rate, the
need for target lesion revascularization (TLR) and major adverse cardiac events (MACE).
Results: At 10-month angiographic follow-up, in-stent late lumen loss was 0.20  0.53
mm and 0.11  0.49 mm (p0.28), and angiographic restenosis rate was 3.8 % and 5.2
% (p0.72) in the EES and SES groups, respectively. At 18-month clinical follow-up,
MACE events had occurred in 15 (14%) patients in the EES group and 18 (17%) patients
in SES group (p0.53), with TLR performed in 5 (5%) and 8 (8%) patients in the two
groups (p0.37).
Conclusions: Stent implantation with EES or SES is associated with similar angio-
graphic and clinical outcome in patients with diabetes mellitus and coronary artery
disease.
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Background: Renal artery sympathetic denervation using radiofrequency (RF) energy
has been shown to reduce blood pressure in patients with resistant hypertension. However,
energy forms like RF which rely on conductive heating cause transmural arterial damage
before achieving denervation of the periarterial sympathetic nerve plexus. In vitro and
pre-clinical testing has demonstrated that therapeutic ultrasound energy can induce
differential injury to the nerve fibers while sparing the arterial wall. We now report on the
preliminary results of a first-in-human feasibility trial with this novel therapeutic
ultrasound system in patients with refractory hypertension.
Methods: Ten patients with a history of drug-resistant hypertension were enrolled
in the SOUND-ITV study. The ultrasound catheter (Sound Interventions, Inc,
Stony Brook, NY), incorporating a cylindrical transducer encased within a novel
non-cylindrical, non-occlusive balloon was advanced into the renal arteries
through a sheath. Ultrasound energy was delivered in a circumferential manner to
both renal arteries; an average of 1.8 applications were delivered to each renal
artery. Energy delivery time was less than 2 minutes per patient. Renal artery
diameters ranged from 5.0-8.6 mm.
Results: Patients with a baseline systolic office BP  160 mmHg demonstrated a
significant reduction in the office BP at 1 month follow-up: the average BP drop of -31/-10
mmHg. All patients tolerated the procedures well with deep sedation. There was no device
or energy-related spasm. Acutely and through follow-up, there were no device or
procedure related complications. Arteries were assessed post procedure by angiography
(n10) and IVUS (n7). No changes in arterial size were observed.
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